Author

A. Westhorpe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. Crittenden· 2 shared J. Alsolaiss· 2 shared N. R. Casewell· 2 shared R. A. Harrison· 2 shared R. J. Edge· 2 shared S. K. Menzies· 2 shared S. R. Hall· 2 shared B. Thomas· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

E. Crittenden

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: results of preclinical efficacy testing

S. K. Menzies, T. Litschka-Koen, R. J. Edge, J. Alsolaiss, E. Crittenden, S. R. Hall, A. Westhorpe, B. Thomas, J. Murray, N. Shongwe, S. Padidar, D. G. Lalloo, N. R. Casewell, J. Pons, R. A. Harrison

This study evaluates two antivenoms as alternatives to SAIMR Polyvalent in Eswatini, finding they are equally or more effective against the most common snake venom but less effective against others.

bioRxiv · May 16, 2022Pharmacology & Toxicology

In vitro and in vivo venom-inhibition assays identify metalloproteinase-inhibiting drugs as potential treatments for snakebite envenoming by Dispholidus typus

S. K. Menzies, R. H. Clare, C. Xie, A. Westhorpe, S. R. Hall, R. J. Edge, J. Alsolaiss, E. Crittenden, R. A. Harrison, J. Kool, N. R. Casewell

This study evaluates four SVMP inhibitors for treating D. typus snakebite envenoming, finding DMPS and marimastat effective in preclinical models.

bioRxiv · Jan 7, 2022 · PreprintPharmacology & Toxicology